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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is an inflammatory pulmonary disorder with systemic
inflammatory manifestations that are mediated by circulating acute-phase reactants. This study compared an
enzyme-linked immunosorbent assay (ELISA) to a nephelometric technique for the measurement of serum C-
reactive protein (CRP) and serum amyloid A (SAA) and investigated how the choice of assay influenced the
estimation of inflammation in patients with stable COPD.
Methods: CRP and SAA concentrations measured by ELISA and nephelometry in 88 patients with COPD and 45
control subjects were used to evaluate the performance of these methods in a clinical setting.
Results: With both assays, the concentrations of CRP and SAA were higher in COPD patients than in controls after
adjustment for age and sex. There was a moderate correlation between the values measured by ELISA and those
measured by nephelometry (logCRP: r = 0.55, p < 0.001; logSAA: r = 0.40, p < 0.001). However, the concentrations
of biomarkers determined by nephelometry were significantly higher than those obtained with ELISA for CRP
(mean difference = 2.7 (9.4) mg/L) and SAA (mean difference = 0.31 (14.3) mg/L).
Conclusion: Although the serum CRP and SAA concentrations measured by ELISA and nephelometry correlated
well in COPD patients, the ELISA values tended to be lower for CRP and SAA when compared with nephelometric
measurements. International standardization of commercial kits is required before the predictive validity of
inflammatory markers for patients with COPD can be effectively assessed in clinical practice.
Background
Chronic obstructive pulmonary disease (COPD) is a
complex chronic inflammatory disease of the lungs
with significant extrapulmonary effects that may con-
tribute to its severity in individual patients [1,2]. Grow-
ing evidence suggests that markers of systemic
inflammation, such as C-reactive protein (CRP) and
serum amyloid A (SAA), are increased in patients with
COPD compared with control subjects without COPD
[3]. For this reason, low-grade systemic inflammation is
currently considered to be a hallmark of COPD and
one of the key mechanisms that may be responsible for
the increased rate of comorbidity.
CRP is the prototypic acute-phase reactant that belongs
to the highly conserved pentraxin family of plasma pro-
teins. Current evidence indicates that increased CRP levels
can be used to identify subjects who have an increased
risk of developing myocardial infarction, stroke, unstable
angina, or sudden cardiac death [4]. Elevated levels of CRP
in patients with COPD were demonstrated to predict
adverse outcomes and the development of cardiovascular
complications [5]. In recent years, CRP has emerged as a
biochemical marker of systemic involvement in COPD [6],
a prognostic factor [7], and a marker for diagnosis and
prognosis during acute exacerbations [8].
SAA is another acute-phase protein that is expressed
primarily in the liver as a part of the systemic response
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levels rise with systemic inflammation in a manner simi-
lar to that of CRP [10]. Previous studies have suggested
that SAA levels are increased in patients with COPD
exacerbations [11,12] and in those with stable disease
[13].
Although many studies of COPD have reported
changes in various inflammatory markers, their rele-
vance to the systemic manifestations of the disease is
still unclear and is probably not causal [14]. In this
regard, many questions concerning the selection of
appropriate cut-off values for clinical use, the exact
source of different inflammatory markers, and the
impact of these markers on the systemic manifestations
of COPD remain unanswered [15]. An important caveat
is the current lack of standardization of the various ana-
lytical assays. Several analytical techniques, including
enzyme-linked immunosorbent assays (ELISA) [13],
nephelometry [12], chemiluminescent assays [6], and
latex-enhanced immunoturbidimetric assays [16], have
been developed to measure serum levels of inflamma-
tory markers. A comparison of methods is usually
recommended when two or more analytical assays are
available in clinical practice. Because the measurements
of inflammatory markers in patients with COPD are
intended for clinical use, a difference of any given mea-
surement method from another is clinically acceptable
o n l yw h e nt h ed i a g n o s t i co rp r o g n o s t i ca s p e c t sa r en o t
impaired. In this context, the question arises whether
the laboratory technique used to measure serum con-
centrations of CRP and SAA can affect the interpreta-
tion of the results.
In the present study, we sought to compare an ELISA
assay to a nephelometric technique for the measurement
of CRP and SAA in patients with stable COPD and to
investigate how the assay choice can influence estimates
of inflammation in this group of patients.
Methods
Participants
This case-control study was conducted at the University
Hospital Virgen del Rocio, Seville, Spain. All analyses
were conducted in a cross-sectional fashion. Recruit-
ment of cases and controls (2:1 ratio) occurred between
May 2007 and November 2009 in our outpatient pul-
monary clinic. Ethical approval for the study was
granted by the local Institutional Ethics Committee
(Comité de Ética e Investigación Clínica del Hospital
Universitario Virgen del Rocío, Seville, Spain), and writ-
ten informed consent was obtained from all participants.
The inclusion criteria for the cases comprised the fol-
lowing: (a) a diagnosis of COPD with a forced expiratory
volume in 1 second (FEV1)/forced vital capacity (FVC)
ratio < 0.7 and (b) a negative history of acute
exacerbations in the previous three months. Control
subjects were recruited among persons who attended
our tobacco weaning clinic. Smokers aged > 40 years
with a FEV1/FVC ratio ≥ 0.7 were considered eligible
for inclusion as controls. In all participants, the smoking
status was confirmed by exhaled carbon monoxide
measurement.
The exclusion criteria for cases and controls included
a previous history of ischemic heart disease, congestive
heart failure, ventilator dependency, malignancy, hepatic
cirrhosis, end-stage renal disease, rheumatologic disor-
ders, tuberculosis, orthopedic conditions precluding per-
formance in the walking and cardiopulmonary exercise
tests, neurological or psychiatric illnesses that could
interfere with the participation in the study, or any sys-
temic infection or inflammatory process that could be
associated with increased CRP or SAA concentrations.
All participants underwent a cardiopulmonary exercise
test to rule out the presence of ischemic heart disease. If
the test was positive, the subject was excluded from the
study and referred to the cardiology department for
appropriate care.
Clinical assessment
To characterize the sample, one author (JLLC) assessed
all of the participants using a standardized questionnaire
that included questions on the presence of comorbidities,
respiratory symptoms, and current medication use. The
patients’ anthropometric measures were collected in a
standard fashion. A detailed medical history was obtained
from all participants. Comorbidities were determined
using the Charlson-age index [17]. All patients under-
went spirometric tests according to the international
standards [18]. Functional dyspnea was scored using the
modified Medical Research Council scale [19].
Exercise testing was performed on a cycle ergometer
MasterScreen CPX (ViaSys Healthcare, Hoechberg, Ger-
many) while breathing room air. The protocol consisted
of the following steps: 3 minutes of rest and 1 minute of
no-load work, followed by a 15 Watts/min exercise rou-
tine with continuous 12 lead electrocardiogram (ECG)
monitoring. The patients exercised until exhaustion or
evidence of ischemic heart disease based on clinical cri-
teria or the ECG results. The ECG was interpreted by
an independent physician to assess the presence of exer-
cise-induced myocardial ischemia. Minute ventilation,
oxygen uptake, and carbon dioxide output were mea-
sured breath by breath.
Laboratory methods
Blood samples were drawn by venipuncture before any
test was performed, after the subjects had rested. The sam-
ples were stored in a -70°C freezer until measurement.
Serum CRP (R&D System, Minneapolis, MN, USA) and
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tions were measured using commercially available high-
sensitivity ELISA assays. Both biomarkers were also mea-
sured by immunonephelometry (Ne) (Dade Behring, Mar-
brug, Germany) according to the manufacturer’s
instructions. The use of both measurement methods in
this study was justified by the availability of both techni-
ques in our institute. In addition, we have our own experi-
enced personnel dedicated to their determination. The
minimum detection limits of the nephelometric assay
were 0.16 mg/L and 0.28 mg/L for CRP and SAA, respec-
tively. The minimum detection limits of the ELISA assays
for CRP and SAA were 10
-4 mg/L and 0.011 mg/L, respec-
tively. All samples were identified by a numerical code and
analyzed in a random order. These assays were performed
by an investigator who was blinded to the sources of the
samples. Each sample was analyzed and duplicated, and
the mean value of the two measures was used for the
analyses.
ELISA measurements of CRP were performed in a
final volume of 50 μL using 100-fold diluted serum sam-
ples. Samples were added to a 96-well microtiter plate
that was pre-coated with a mouse monoclonal antibody
specific to CRP and then incubated for 2 h. After four
washes, the sera were incubated for 2 h with horseradish
peroxidase (HRP)-conjugated anti-CRP antibodies for
detection. The plates were washed four times, the sub-
strate solution was then added, and the plates were
incubated for 30 min. Finally, 50 μLo fs t o ps o l u t i o n
was added to each well, and the color changed from
blue to yellow. The optical density of each well was
measured at 450 nm using a microplate reader (Tecan,
Männedorf, Switzerland). The results were linearized by
plotting the log of the CRP concentration versus the log
of the optical density, and the best fit line was deter-
mined by regression analysis. Because the samples were
previously diluted, the concentrations read from the
standard curve were corrected by the dilution factor.
SAA was determined by ELISA following the recom-
mended protocol. Serum samples were diluted twice to a
final dilution of 1:50. Aliquots (100 μL) of each sample
were added to a microtiter plate that was pre-coated with
am o n o c l o n a la n t i b o d ys p e c i f i cf o rS A Aa n di n c u b a t e d
for 1 h. After five washes, a horseradish peroxidase-con-
jugated polyclonal antibody specific for SAA was added
for 1 h. The plate was washed five times, and the sub-
strate solution was added for 15 min. Finally, a stop solu-
tion was added, and the optical density was read at 450
nm using a microplate reader (Tecan, Männedorf, Swit-
zerland). The standard curve provided in the kit was used
to determine the amount of SAA in the unknown sam-
ples. To determine the final concentration of SAA serum,
the concentration read from the standard curve was mul-
tiplied by the dilution factor.
The nephelometric determinations of CRP were per-
formed using a polystyrene-enhanced immunonephelo-
metric method on a Dimension Vista System (Siemens,
Munich, Germany). Commercially available kits were
used (Dade Behring, Marburg, Germany). The nephelo-
metric determinations of SAA were performed using a
latex-enhanced immunonephelometric method on a
Dade Behring BN2 Nephelometer Analyzer equipped
with commercially available kits (Dade Behring, Mar-
burg, Germany).
Statistical analysis
All statistical analyses were performed using Predictive
Analytics Software, version 18.0 (PASW; IBM Corpora-
tion, Somers, New York, USA). The normality of the
distribution was checked for all continuous variables;
skewed data were log-transformed before further analy-
sis. Normally distributed variables are expressed as
arithmetic means with standard deviations in parenth-
eses. Qualitative variables are summarized as absolute
and relative frequencies. The reference values for each
marker in the study cohort were determined by calculat-
ing the mean and the 95% confidence interval in the
control group for each technique. Differences in contin-
uous variables were assessed using Student’s t test for
independent samples (including Levene’st e s tf o rv a r -
iance similitude analysis). The c
2 test and Fisher’se x a c t
test were used for categorical variables. The association
of CRP and SAA values between cases and controls was
assessed using Student’s t test for independent samples
(including Levene’s test for variance similitude analysis).
This association was further tested using a binomial
multiple logistic regression analysis for which sex and
age were included as covariates. The results of this ana-
lysis are expressed as adjusted odds ratios (ORs) with
95% confidence intervals (CIs).
We also investigated the differences between the two
analytical methods for the measurements of CRP and
SAA. First, we compared the mean values obtained via
the two techniques using a paired Student’s t test. Sec-
ond, we performed a simple linear correlation analysis
using Pearson’s correlation coefficient. The degree of
correlation was evaluated using the criteria of Brennan
and Silman [20]. We then tested the degree of agree-
ment between the two analytical methods using the
Bland-Altman plot of difference versus mean [21].
Because no universally accepted cut-off values for CRP
and SAA exist, we considered the average value of the
mean concentrations that were obtained using the two
techniques in the control group as a reference. We then
calculated the number of patients who had levels of
each inflammatory marker above the reference value for
each technique and subsequently calculated the kappa
coefficient. The results are expressed as mean changes
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deemed to be statistically significant.
Results
In total, 88 COPD cases and 45 controls were recruited
into the study. The characteristics of the participants are
shown in Table 1. The distribution of COPD stages was
a sf o l l o w s :G O L DI ,1 4p a t i e n t s( 1 5 . 9 % ) ;G O L DI I ,4 1
patients (46.6%); GOLD III, 19 patients (21.6%); and
GOLD IV, 14 patients (15.9%). The COPD patients were
being treated with inhaled steroids (56.8%), long-acting
ß2 agonists (55.7%), and tiotropium (50%). The mean
dose of inhaled corticosteroids in the COPD group was
844 (377) μg of fluticasone or equivalent per day.
Concentrations of acute phase reactants
Compared with controls, the levels of CRP were higher
in COPD patients as measured using both assays (CRP
(Ne) 7.3 (11.8) vs. 3.3 (3.2) mg/L, p = 0.002; CRP
(ELISA) 3.4 (3.2) vs. 2.9 (3.9) mg/L, p = 0.026; Figure 1,
Table 2). This difference persisted even after adjustment
for age and sex in a multivariable logistic regression
model. The adjusted odds ratio for the increased CRP
levels (log-transformed) in patients with COPD com-
pared with controls was 3.1 (95% CI: 1.2 to 8.0). The
mean value for CRP in the control group was 3.3 mg/L
(95% CI: 2.4-4.3 mg/L) for the nephelometric assay and
2.9 mg/L (95%CI: 1.7-4.1 mg/L) for ELISA. Thus, the
cut-off value for a normal level was set at 3.1 mg/L. In
the COPD group, the mean CRP levels did not differ
significantly between smokers and previous smokers
(data not shown). Treatment with corticosteroids had
no impact on the CRP levels, as assessed by both assays.
SAA levels measured by ELISA and nephelometry
were found to be higher in COPD patients compared
with controls (SAA (Ne) 11.0 (17.4) vs. 5.3 (4.7) mg/L, p
= 0.022; SAA (ELISA) 9.9 (8.1) vs. 6.6 (7.4) mg/L, p =
0.003; Figure 1, Table 2). This difference persisted even
after age and sex were accounted for in a multivariable
logistic regression model. The adjusted OR for increased
SAA levels (log-transformed) in patients with COPD
compared with controls was 2.6 (95% CI: 1.06 to 6.6).
The mean value for SAA in the control group was 5.3
mg/L (95% CI: 3.9-6.8 mg/L) for the nephelometric
assay and 6.8 mg/L (95% CI: 4.4-9.1 mg/L) for ELISA.
Thus, the cut-off value for a normal level was set at 6.05
mg/L. In the COPD group, the mean SAA levels did not
differ significantly between smokers compared and pre-
vious smokers (data not shown). Treatment with corti-
costeroids had no impact on SAA levels, as assessed by
both assays.
Comparison between the two assays
The levels of SAA were significantly higher than those
of CRP for cases and controls and for both techniques,
which indicated a consistently higher expression of SAA
(Figure 1, Table 2 p < 0.05 for all comparisons). The
levels of CRP (log-scale) correlated moderately with
those of SAA (log-scale) as measured by both techni-
ques (Ne: r = 0.54, p < 0.001; ELISA: r = 0.31, p <
0.001). A moderate positive correlation between ELISA
and nephelometry measurements was also observed
(logCRP: r = 0.55, p < 0.001; logSAA: r = 0.40, p <
0.001). All correlations retained their statistical signifi-
cance even when the patients and controls were ana-
lyzed separately (data not shown).
Assay agreement
The results of the Bland-Altman plots for nephelometry
and ELISA are depicted in Figure 2. There was a consis-
tent difference between the two techniques. Specifically,
the values obtained using nephelometry were signifi-
cantly higher than those obtained using ELISA for both
CRP and SAA (Table 3). These differences were even
more pronounced when the COPD patients were ana-
lyzed separately (Table 3). In the entire sample, the
kappa coefficients were 0.34 for CRP (p < 0.001) and
0.21 for SAA (p = 0.015). The patients with COPD
showed similar results: specifically, the kappa coeffi-
cients were 0.26 (p = 0.007) and 0.23 (p = 0.033) for
CRP and SAA, respectively.
Discussion
In this study, results from nephelometry and ELISA
were compared in a sample of stable COPD patients.
This study provides insight into how assay differences
may influence the estimates of inflammation in clinical
settings. We are not aware of any other report that has
addressed this important clinical and research issue. In
fact, the usefulness of systemic biomarkers has been
Table 1 Baseline characteristics of the study participants
Entire cohort
(n = 133)
COPD
(n = 88)
Controls
(n = 45)
p value*
Male sex 111 (83.5%) 81 (92%) 30 (66.7%) < 0.001
Age (years) 62.5 (9.2) 65.4 (7.8) 56.9 (9.2) < 0.001
BMI (kg/m
2) 27.6 (5) 27.6 (5) 27.6 (4.9) NS
Smoking (pack-yr) 56.4 (25.9) 62.2 (25) 45.3 (24.3) < 0.001
Charlson-age 3.11 (1.5) 3.7 (1.2) 1.8 (1.4) < 0.001
Exhaled CO (ppm) 8.5 (9.7) 6.5 (7.7) 13.9 (12.4) 0.015
FVC (%) 92.7 (17.4) 92.7 (19) 92.8 (13.8) NS
FEV1 (%) 69.1 (23.4) 58.9 (20.5) 90 (12.8) < 0.001
Dyspnea (MRC) 0.86 (0.67) 0.97 (0.68) 0.64 (0.6) 0.009
Data expressed as mean (standard deviation) or absolute (relative)
frequencies, as appropriate. *Data were analyzed using Student’s t test or the
c
2 test, as appropriate.
FVC: Forced vital capacity. FEV1: Forced expiratory volume in 1 second. BMI:
body mass index. CO: carbon monoxide. MRC: Medical Research Council scale.
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room and intensive care unit and during hospitalization)
and for a number of diseases; therefore, the standardiza-
tion of technical assays is necessary for all biomarker
studies to provide meaningful data. We were also able
to confirm that stable COPD is associated with an
increase in CRP and SAA levels compared with healthy
controls, which suggests t h ep r e s e n c eo fas y s t e m i c
inflammatory load, as previously described [3].
Extensive research has investigated the relevance of
different inflammatory markers in COPD. CRP and SAA
are major acute-phase reactants in humans that are
synthesized in the liver by factors that initiate and main-
tain the inflammatory response, such as interleukin (IL)-
1, IL-6, and tumor necrosis factor a. Although several
inflammatory mediators induce and control the secre-
tion of these biomarkers, CRP is predominantly induced
by IL-6, whereas SAA is stimulated mainly by IL-1 [9].
Increased levels of CRP may reflect the severity of air-
way inflammation [22] with a strong prognostic value
Figure 1 Concentrations of CRP and SAA measured by the two analytical assays (nephelometry and ELISA) in COPD patients and
healthy controls. Panel a) CRP by nephelometry. Panel b) CRP by ELISA. Panel c) SAA by nephelometry. Panel d) SAA by ELISA.
Table 2 Log-transformed concentrations of CRP and SAA
measured by the two analytical assays (nepholometry
and ELISA) in COPD patients and healthy controls
Entire cohort
(n = 133)
COPD
(n = 88)
Controls
(n = 45)
p value*
logCRP (Ne) 0.5 (0.4) 0.6 (0.4) 0.3 (0.4) 0.002
logCRP (ELISA) 0.2 (0.6) 0.3 (0.5) 0.04 (0.7) 0.026
P value† < 0.001 < 0.001 0.001
logSAA (Ne) 0.7 (0.4) 0.7 (0.4) 0.5 (0.3) 0.022
logSAA (ELISA) 0.7 (0.4) 0.8 (0.4) 0.5 (0.5) 0.003
P value† NS NS NS
Data expressed as the mean (standard deviation). *p value calculated by
unpaired Student’s t test. †p value for the difference between nephelometry
and ELISA calculated by paired Student’s t test.
logCRP (Ne): log-transformed concentrations of C-reactive protein measured
by nephelometry.
logCRP (ELISA): log-transformed concentrations of C-reactive protein measured
by ELISA.
logSAA (Ne): log-transformed concentrations of serum amyloid A measured by
nephelometry.
logSAA (ELISA): log-transformed concentrations of serum amyloid A measured
by ELISA.
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in cardiovascular diseases [24]. Of note, this molecule
can provide prognostic information beyond that which
is conveyed by the Framingham risk score [25].
However, the exact pathophysiological relevance of high
CRP levels remains controversial. A previous study
linked CRP to plasma low-density lipoprotein, which
may play a significant role in modulating CRP function
Figure 2 Bland-Altman plot showing the agreement between CRP and SAA values between the two assays. Panel a) logCRP. Mean
difference: 0.29 (95% CI: -0.77 to 1.37).. Panel b) logSAA. Mean difference: -0.02 (95% CI: -1.04 to 1.0008).
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these data suggest that CRP may be involved in lipopro-
tein metabolism, clearance, and deposition.
Increased SAA concentrations have been reported in a
number of chronic inflammatory and neoplastic diseases
that have been linked to systemic amyloid deposition
[27]. Higher serum SAA levels are also associated with
COPD exacerbation and are more predictive than CRP
for the severity of these episodes [11]. Growing evidence
has suggested that SAA may act as an apoprotein. SAA
is involved in the conformational change in the high
density lipoprotein (HDL) particle [28] and causes
increased HDL clearance [29,30]. In light of these find-
ings, it has been hypothesized that increased SAA levels
can contribute to accelerated atherosclerosis in stable
COPD [13].
Although we found statistically significant method-
dependent differences for CRP and SAA, specific differ-
ences for each biomarker were noted. First, the distribu-
tion of each molecule is noteworthy. As shown in
Figure 1, both of the acute phase reactants displayed a
wider distribution when measured using nephelometry
in COPD compared with the ELISA assays or measure-
ments obtained from the control group. This finding
may at least in part explain our results that suggest a
more pronounced difference in COPD patients than in
controls. This difference is reflected in the standard
deviations, which were higher when the biomarkers
were measured using nephelometry in the COPD group.
Interestingly, this wide distribution has also been
reported by other authors who have used different
laboratory techniques (e.g., a high sensitivity chemilumi-
nescent immunoassay) [6]. Additionally, the differences
between the two techniques were less marked for SAA
than for CRP. When the two methods were compared
directly (Tables 2 and 3), the differences in SAA levels
did not reach the threshold for significance. However,
the analysis of agreement showed a consistent difference
between the two methods. As shown by the Bland-Alt-
man test, such differences may be clinically important
for COPD patients. It is also noteworthy that the kappa
coefficient was low.
Despite the high sensitivity, speed, and accuracy as
well as the good correlation of nephelometry with other
techniques in humans [31,32] and animal models [33],
the agreement of this technique with ELISA has not
been previously investigated in patients with COPD.
Interestingly, a discrepancy between these techniques
w a sr e p o r t e di na na n a l y s i so fc e r e b r o s p i n a lf l u i dI g G
[34]. The present study showed that although the con-
centrations of inflammatory markers obtained using
nephelometry and ELISA were moderately correlated,
the agreement between the two assays is remarkably
low. It is now well-recognized that a good degree of cor-
relation does not necessarily imply a good agreement,
and vice versa [21]. Although the two assays correlate
well, they may provide different information about
COPD patients that could ultimately lead to different
conclusions concerning the prognostic significance of
the biomarkers.
In this regard, the effect of the assay differences on
the selection of appropriate cut-off values for different
inflammatory markers is a clinically important issue and
therefore must be more precisely characterized. To our
knowledge, only one study using nephelometry has
attempted to identify a reliable cut-off for increased
CRP concentrations (4.21 mg/L) in patients with chronic
respiratory disorders [35]. However, other authors have
used 3.0 mg/L as a cut-off for high CRP levels that were
measured using nephelometry [5]. Although we esti-
mated a cut-off value of 3.1 mg/L for CRP in this study,
we found robust evidence of a significant analytical dif-
ference between nephelometry and ELISA for the mea-
surement of serum inflammatory markers, with a more
marked difference in COPD patients. Although the rea-
sons for the analytical differences between the two
assays remain unclear, such a large difference is likely to
be clinically significant. It is remarkable in this regard
that a difference of 3.9 units for CRP in COPD patients
may overcome the threshold value for poor prognostic
significance, i.e., 4.21 [35], 3.0 [5] or 3.1 mg/L (the cur-
rent study).
Although the differences between the assays were less
pronounced for SAA, the same reasoning can be applied
to this biomarker. The reference values for SAA in
healthy individuals have not yet been thoroughly estab-
l i s h e d .T oo u rk n o w l e d g e ,t h e r ei so n l yo n es t u d yo n
this issue, which identified a threshold value of 7.0 mg/L
using an ELISA assay [22]. Of note, this cut-off agrees
with that identified in the present study. Using these
thresholds, a method-dependent difference of 1.2 mg/L
accompanied by a large standard deviation (Table 3)
may have a significant impact on the prognostic signifi-
cance of this marker in a clinical setting. However, a
long-term follow-up of the patients would provide
insight as to whether these differences in measurements
are relevant from a clinical point of view and would
determine the variability and reliability of both markers
Table 3 Mean differences in CRP and SAA values
measured by the two analytical assays (nepholometry
and ELISA) in COPD patients and healthy controls
Entire cohort
(n = 133)
COPD
(n = 88)
Controls
(n = 45)
p value*
CRP (mg/L) 2.7 (9.4) 3.9 (11.1) 0.4 (4.1) 0.009
SAA (mg/L) 0.31 (14.3) 1.2 (17.2) -1.4 (5.9) NS
NS, not significant
* p value calculated by unpaired Student’s t test.
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in the present study did not include this follow-up.
Future trials should evaluate this aspect in a prospective
cohort.
The relationship between inhaled corticosteroid use
and the systemic inflammatory load in COPD is a
source of debate. In an initial small study, the use of
inhaled corticosteroids at a dose of 1,000 μgo ff l u t i c a -
sone per day was shown to be effective in reducing
serum CRP levels in patients with COPD [36]. However,
several years later, the same group found that this asso-
ciation was not present for CRP in a clinical trial multi-
center study with a larger sample size [37]. The present
study did not show this association, and our results thus
provide further evidence for the lack of association.
Conclusions
In conclusion, the nephelometry values in the present
s t u d yt e n d e dt ob eh i g h e rf o rb o t hC R Pa n dS A Ac o m -
pared to ELISA measurements in COPD patients. These
differences should carefully be considered, as they may
actually overcome the commonly accepted threshold
values. These findings suggest the presence of a hereto-
fore unrecognized issue in the assessment of systemic
inflammation in COPD. International standardization of
commercial kits is required before the predictive validity
of inflammatory markers for patients with COPD can be
effectively assessed in clinical practice. Our results high-
light the need for the use of the same analytical proce-
dures when comparing results obtained from different
studies. Because standardization is not yet available, stu-
dies on inflammatory biomarkers in COPD patients
should always include a control group.
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